Caribou Biosciences' Chief Business Officer, Ruhi Ahmad Khan, reported a sale of 6,938 shares of the company's common stock on February 24, 2026, at a price of $1.96 per share, resulting in proceeds of $13,598, according to a Form 4 filing with the Securities and Exchange Commission. The filing states the sale was executed to satisfy tax liabilities tied to the vesting of restricted stock units.
The disclosure also records activity earlier that week. On February 20, 2026, Khan acquired 45,000 shares of Caribou Biosciences common stock with a recorded value of $0. In addition, the CBO received option grants allowing the purchase of 202,500 common shares at an exercise price of $1.80. Those options vest on a monthly basis and are scheduled to be fully vested by February 20, 2030.
Following the February transactions, Khan is listed as directly owning 104,998 shares of the company.
These insider transactions coincide with significant recent moves in the company's market performance. Caribou Biosciences' shares have gained 32% over the past week and are up 73% over the last 12 months. Complementing market action, proprietary analysis from InvestingPro indicates CRBU is currently trading below its assessed Fair Value, which the platform interprets as potential upside. The InvestingPro Pro Research Report - made available for CRBU and more than 1,400 U.S. equities - assigns Caribou Biosciences an overall financial health score of "FAIR".
On the research front, Clear Street has initiated coverage of Caribou Biosciences with a Buy rating and established a price target of $13.00. That firm highlighted optimism surrounding Caribou's development efforts in off-the-shelf allogeneic CAR-T cell therapies, projecting these programs as potential commercial competitors in the cell therapy market. Clear Street framed this outlook as a positive signal for the company's strategic direction and market prospects, noting analyst coverage can affect investor sentiment and provide context on growth potential.
Taken together, the regulatory filing and recent analyst interest underscore active attention on Caribou Biosciences from both insiders and the investment community. The transactions reported by Khan were administrative in nature - specifically to meet tax obligations - while the grants and options outline a longer-term compensation and retention schedule tied to the company’s future performance.
Although the filing provides a clear ledger of the transactions and holdings, it does not include further commentary from Khan or the company regarding the rationale beyond the stated tax-coverage purpose, nor does it provide information on any intended future trades.